IS8392A - Heterósýklískir hindrar MEK og notkun þeirra - Google Patents

Heterósýklískir hindrar MEK og notkun þeirra

Info

Publication number
IS8392A
IS8392A IS8392A IS8392A IS8392A IS 8392 A IS8392 A IS 8392A IS 8392 A IS8392 A IS 8392A IS 8392 A IS8392 A IS 8392A IS 8392 A IS8392 A IS 8392A
Authority
IS
Iceland
Prior art keywords
heterocyclic
inhibits mek
mek
inhibits
heterocyclic inhibits
Prior art date
Application number
IS8392A
Other languages
English (en)
Icelandic (is)
Inventor
M. Wallace Eli
Hurley Brian
Woon Yang Hoon
P. Lyssikatos Joseph
L. Marlow Allison
Blake Jim
Original Assignee
Array Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc. filed Critical Array Biopharma Inc.
Publication of IS8392A publication Critical patent/IS8392A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8392A 2003-09-03 2006-03-31 Heterósýklískir hindrar MEK og notkun þeirra IS8392A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/654,580 US7144907B2 (en) 2003-09-03 2003-09-03 Heterocyclic inhibitors of MEK and methods of use thereof
US10/929,295 US7230099B2 (en) 2003-09-03 2004-08-30 Heterocyclic inhibitors of MEK and methods of use thereof
PCT/US2004/028649 WO2005023759A2 (en) 2003-09-03 2004-09-01 Heterocyclic inhibitors of mek and methods of use thereof

Publications (1)

Publication Number Publication Date
IS8392A true IS8392A (is) 2006-03-31

Family

ID=34218110

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8392A IS8392A (is) 2003-09-03 2006-03-31 Heterósýklískir hindrar MEK og notkun þeirra

Country Status (18)

Country Link
US (5) US7144907B2 (https=)
EP (1) EP1673339B1 (https=)
JP (1) JP4131741B2 (https=)
KR (1) KR20060070558A (https=)
CN (1) CN1874769A (https=)
AR (1) AR046081A1 (https=)
AU (1) AU2004270699B2 (https=)
BR (1) BRPI0414111A (https=)
CA (1) CA2537321A1 (https=)
IL (4) IL173936A (https=)
IS (1) IS8392A (https=)
MX (1) MXPA06002466A (https=)
NO (1) NO20061506L (https=)
PT (1) PT1673339E (https=)
RU (1) RU2006109599A (https=)
TW (1) TW200526607A (https=)
WO (1) WO2005023759A2 (https=)
ZA (1) ZA200602581B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2546353A1 (en) * 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
JP2008521858A (ja) * 2004-12-01 2008-06-26 ラボラトワール セローノ ソシエテ アノニム 過増殖性疾患を処置するための［１，２，４］トリアゾロ［４，３−ａ］ピリジン誘導体
US7666880B2 (en) * 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
TW200714600A (en) * 2005-03-21 2007-04-16 S Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
SG177981A1 (en) * 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CA2608890C (en) * 2005-05-20 2011-08-02 Alantos-Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
HRP20110498T1 (hr) * 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) * 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
ES2376771T3 (es) * 2006-08-21 2012-03-16 Genentech, Inc. Compuestos aza-benzofuranilo y métodos de utilización
ES2528797T3 (es) * 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
RU2444524C2 (ru) * 2006-08-21 2012-03-10 Дженентек, Инк. Азабензотиофенильные соединения и способы применения
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
EP2070927A4 (en) 2006-09-13 2010-10-13 Kyowa Hakko Kirin Co Ltd CONDENSED HETEROCYCLIC DERIVATIVE
EA201300152A1 (ru) * 2006-11-27 2013-07-30 Х. Лундбекк А/С Гетероариламидные производные
WO2008076415A1 (en) * 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
BRPI0809567A2 (pt) * 2007-04-10 2014-09-23 Lundbeck & Co As H Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto
NZ582098A (en) 2007-06-25 2012-03-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009064675A1 (en) * 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
AU2008343065B2 (en) * 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
PT2231662E (pt) * 2007-12-19 2011-09-12 Genentech Inc 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
MX2010014565A (es) * 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
EA021293B1 (ru) 2008-12-08 2015-05-29 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
KR101489045B1 (ko) * 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN103168039B (zh) 2010-03-11 2016-08-03 吉利德康涅狄格公司 咪唑并吡啶类syk抑制剂
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
ES2658395T3 (es) 2012-04-04 2018-03-09 Rigel Pharmaceuticals, Inc. Inhibidores de proteína cinasa C y usos de los mismos
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
AU2013269809B2 (en) 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
MA38085B1 (fr) 2012-10-12 2018-11-30 Exelixis Inc Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2904610A1 (en) 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
UA118846C2 (uk) 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN103980217B (zh) * 2014-05-26 2015-12-30 南京林业大学 一类蒎烷基异噁唑类化合物及其合成方法和应用
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
CN107759532B (zh) * 2017-11-23 2021-02-12 苏州大学 一种苯并噁唑-2-乙基肟衍生物、其制备方法及应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
CA2116117A1 (en) 1991-08-22 1993-03-04 Hiroyuki Sueoka Benzisoxazole compound and use thereof
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1995003286A1 (en) 1993-07-23 1995-02-02 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
DE19517448A1 (de) * 1995-05-12 1996-11-14 Thomae Gmbh Dr K Neue Benzothiazole und Benzoxazole, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
EP0977733B1 (en) 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EA002546B1 (ru) 1997-02-11 2002-06-27 Пфайзер Инк. Производные арилсульфонилгидроксамовой кислоты
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
CA2290509A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
HUP0105092A3 (en) 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2355470C (en) 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
EP1144372B1 (en) 1999-01-13 2005-11-30 Warner-Lambert Company Llc Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
EP1150950A2 (en) 1999-01-13 2001-11-07 Warner-Lambert Company Anthranilic acid derivatives
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003504400A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
KR20030059115A (ko) 2000-08-25 2003-07-07 워너-램버트 캄파니 엘엘씨 Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
EP1337524A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents
US6748692B2 (en) * 2001-10-23 2004-06-15 Travis Sprouse Spinner bait
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof

Also Published As

Publication number Publication date
EP1673339A4 (en) 2009-04-29
US7271178B2 (en) 2007-09-18
CA2537321A1 (en) 2005-03-17
TW200526607A (en) 2005-08-16
JP4131741B2 (ja) 2008-08-13
KR20060070558A (ko) 2006-06-23
IL219671A0 (en) 2012-06-28
WO2005023759A2 (en) 2005-03-17
US20060189668A1 (en) 2006-08-24
WO2005023759A3 (en) 2005-09-22
EP1673339B1 (en) 2013-07-03
IL173936A (en) 2012-07-31
US20060189649A1 (en) 2006-08-24
EP1673339A2 (en) 2006-06-28
US7144907B2 (en) 2006-12-05
MXPA06002466A (es) 2006-06-20
US7230099B2 (en) 2007-06-12
NO20061506L (no) 2006-06-02
US20050049419A1 (en) 2005-03-03
CN1874769A (zh) 2006-12-06
IL219670A (en) 2013-03-24
RU2006109599A (ru) 2007-10-10
AR046081A1 (es) 2005-11-23
IL173936A0 (en) 2006-07-05
IL219669A0 (en) 2012-06-28
AU2004270699B2 (en) 2011-11-10
PT1673339E (pt) 2013-07-29
US20060189808A1 (en) 2006-08-24
JP2007504241A (ja) 2007-03-01
AU2004270699A1 (en) 2005-03-17
IL219670A0 (en) 2012-06-28
US20050054701A1 (en) 2005-03-10
ZA200602581B (en) 2007-06-27
BRPI0414111A (pt) 2006-10-31
US7511058B2 (en) 2009-03-31

Similar Documents

Publication Publication Date Title
IS8392A (is) Heterósýklískir hindrar MEK og notkun þeirra
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
NO2017017I1 (no) umeklinidium og vilanterol
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
IS8146A (is) Setnar 3-alkýl og 3-alkenýl asetidín afleiður
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
IS8458A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
DK1648426T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
IS3007B (is) Ónæmisbælandi efnasambönd og efnablöndur
NO20044617L (no) Substituerte benzazoler og anvendelse derav som RAF kinaseinbibitorer
DK1527067T3 (da) 4-Trifluormethylpyrazolylsubstituerede pyridiner og pyrimidiner
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
NO20054083D0 (no) Nye sammenkoblede triazoloner og deres anvendelse
IS8453A (is) Fyrirtækjamatsbúnaður og fyrirtækjamatsforrit
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
IS8529A (is) Rífamísínhliðstæður og notkun þeirra
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
IS7577A (is) Arómatísk súlfón og læknisfræðileg notkun þeirra
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
IS8040A (is) Arómatískt oxýfenýl og arómatískar súlfanýlfenýl afleiður
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav